(cid:4)(cid:393)(cid:393)(cid:286)(cid:374)(cid:282)(cid:349)(cid:454)(cid:3)(cid:4)
`
`John C. Staines, Jr.
`Director & Principal
`
`1200 19th Street, NW
`Washington, DC 20036
`
`Phone: 202-481-8524
`Fax:
`202-973-2401
`Email: john.staines@naviganteconomics.com
`
`EDUCATION
`
`1990 M.B.A., Business Economics and Finance, University of Chicago
`
`1984 M.P.M., Public Policies Toward Business, University of Maryland
`
`1982
`
`B.A., Economics, University of Maryland
`
`PROFESSIONAL POSITIONS
`
`2010-Present Director & Principal, Navigant Economics Manage and conduct economic,
`financial and quantitative analyses related to commercial litigation and
`regulation.
`
`2000-2010
`
`Principal, LECG, LLC Managed and conducted economic, financial and
`quantitative analyses related to commercial litigation and regulation.
`
`1996-2000
`
`Principal, Putnam, Hayes & Bartlett, Inc. Managed and conducted
`economic, financial and quantitative analyses related to commercial litigation
`and regulation.
`
`1990-1995
`
`Associate, Putnam, Hayes & Bartlett, Inc. Conducted economic, financial
`and quantitative analyses related to commercial litigation and regulation.
`
`1985-1988
`
`Associate, Heiden Associates, Inc. Performed economic impact studies of
`proposed environmental and health regulations, economic analyses of
`antitrust issues, and statistical analyses of product safety risk.
`
`1984
`
`Analyst, U.S. Environmental Protection Agency, Office of Policy Analysis.
`Performed economic and risk studies of proposed environmental regulation
`of hazardous wastes.
`
`Exhibit 1139
`IPR2017-00807
`ARGENTUM
`1200 19th Street NW, Suite 700 (cid:135) W(cid:68)(cid:86)hi(cid:81)(cid:74)t(cid:82)(cid:81), (cid:39)(cid:38) 200(cid:22)(cid:25)
`(cid:82)(cid:73)(cid:73)i(cid:70)e(cid:29) 202(cid:17)(cid:23)(cid:27)1(cid:17)(cid:27)(cid:24)2(cid:23) e(cid:80)(cid:68)i(cid:79)(cid:29) (cid:77)(cid:82)h(cid:81)(cid:17)(cid:86)t(cid:68)i(cid:81)e(cid:86)(cid:35)(cid:81)(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)te(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)(cid:17)(cid:70)(cid:82)(cid:80)
`
`000001
`
`

`

`(cid:45)(cid:82)h(cid:81) (cid:38)(cid:17) St(cid:68)i(cid:81)e(cid:86), (cid:45)r(cid:17)
`(cid:39)ire(cid:70)t(cid:82)r (cid:9) (cid:51)ri(cid:81)(cid:70)i(cid:83)(cid:68)(cid:79), N(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)t (cid:40)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)
`(cid:51)(cid:68)(cid:74)e 2 (cid:82)(cid:73) 9
`
`RECENT EXPERT TESTIMONY
`
`(cid:120)
`
`Acrux DDS PTY Ltd. & Acrux Ltd v. Kaken Pharmaceuticals Co., Ltd., and Valeant
`Pharmaceuticals International, Inc., U.S. Patent and Trademark Office, Patent Trial and Appeal
`Board, Case IPR2017-00190, U.S. Patent No. 7,214,506, 2017. (Expert Witness Report and
`Deposition Testimony.)
`
`(cid:120) Hospira, Inc. v. Sylvia Mathews Burwell, Secretary, U.S. Department of Health and Human
`Services; Dr. Margaret Hamburg, Commissioner, U.S. Food and Drug Administration; Par Sterile
`Products, LLC (Intervenor-Defendant), U.S., District Court for the District of Maryland, Case No.
`8:14-cv-02662-GJH, 2014. (Expert Witness Affidavits.)
`
`(cid:120)
`
`(cid:120)
`
`SmithKline Beecham Corp., et al., v. Mylan Laboratories, Inc., et al., U.S., District Court for the
`District of New Jersey, Civ. Action No. 07-2939 (JAP), 2007. (Expert Witness Declaration.)
`
`J.E. Pierce Apothecary, Inc., et al., v. Harvard Pilgrim Healthcare, et al., U.S., District Court for
`the District of Massachusetts, Civ. Action No. 98-CV-12636-RCL, 2003.
`(Expert Witness
`Declaration and Deposition Testimony.)
`
`CONSULTING ACTIVITIES
`
`(cid:120)
`
`Experienced in applying microeconomic, financial, and other quantitative tools and theories in the
`areas of commercial litigation and public policy. Specific areas of experience include the
`economic analysis of markets and competitive effects of various business practices, as well as
`valuation of economic damages in intellectual property, antitrust, and other types of commercial
`litigation, as well as the impact of dumped and subsidized imports in international trade cases
`and economic impact and risk assessment in the context of product liability litigation and
`regulatory rulemakings.
`
`(cid:120) Work has typically included designing and directing data and other economic analyses, drafting
`expert reports, and evaluating analyses submitted by other experts.
`
`(cid:120)
`
`A large proportion of these consulting assignments has involved economic issues arising in the
`Pharmaceutical industry. Other industries studied include: Computers and Peripherals, Software
`Operating Systems, Applications Software, Enterprise Resource Planning Systems,
`Telecommunications, Steel, Coastal Oil Shipping, Oil Refining Equipment, Gasoline wholesaling
`and retailing, Chemicals, Plastics Additives, Wood-Panel Products, Uranium Mining and
`Enrichment, Crushed Stone, Athletic Footwear, Automobiles, Paint Manufacture, and Third Class
`Mail Delivery.
`
`1200 19th Street NW, Suite 700 (cid:135) W(cid:68)(cid:86)hi(cid:81)(cid:74)t(cid:82)(cid:81), (cid:39)(cid:38) 200(cid:22)(cid:25)
`(cid:82)(cid:73)(cid:73)i(cid:70)e(cid:29) 202(cid:17)(cid:23)(cid:27)1(cid:17)(cid:27)(cid:24)2(cid:23) e(cid:80)(cid:68)i(cid:79)(cid:29) (cid:77)(cid:82)h(cid:81)(cid:17)(cid:86)t(cid:68)i(cid:81)e(cid:86)(cid:35)(cid:81)(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)te(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)(cid:17)(cid:70)(cid:82)(cid:80)
`
`000002
`
`

`

`(cid:45)(cid:82)h(cid:81) (cid:38)(cid:17) St(cid:68)i(cid:81)e(cid:86), (cid:45)r(cid:17)
`(cid:39)ire(cid:70)t(cid:82)r (cid:9) (cid:51)ri(cid:81)(cid:70)i(cid:83)(cid:68)(cid:79), N(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)t (cid:40)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)
`(cid:51)(cid:68)(cid:74)e (cid:22) (cid:82)(cid:73) 9
`
`Pharmaceutical Industry Cases
`Analyzed economic, statistical, and financial issues associated with pharmaceutical-related cases
`involving allegations of patent infringement, antitrust violations, proposed regulations, and various
`other commercial claims, as well as regulatory compliance. Specific projects include the following:
`
`Pharmaceutical Patent Infringement
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`Estimated lost profit and reasonable royalty damages associated with alleged sales of
`infringing drugs.
`Zegerid® (ompeprazole) – Ulcers and Gastroesophageal Reflux Disease (“PPI”)
`(cid:16)
`(cid:16) Epivir® (lamivudine) – AIDS treatment
`(cid:16) Nitro-Dur® (nitroglycerin patch) – Angina
`(cid:16) Humulin® (proinsulin) – Type II Diabetes
`(cid:16) Humatrope® (somatropin) – Human Growth Hormone
`
`Analyzed the extent and economic sources of “commercial success” for brand name
`drugs as possible secondary indicia of “nonobviousness” in several Hatch-Waxman
`patent infringement litigations brought against prospective generic entrants and Inter
`Partes reviews sought by prospective generic entrants before the Patent Trial and
`Appeal Board of the U.S. Patent & Trademark Office.
`
`Jublia® (efinaconazole) – Toenail Onychomycosis
`(cid:16)
`(cid:16) Omidria® (ketorolac/phenylephrine) – Cataract Surgery Dilation and Pain Reliever
`(cid:16) Minivelle® (estradiol transdermal patch) – Menopause “Hot Flashes”
`(cid:16) Colcrys® (colchicine) – Gout
`(cid:16) Megace® ES (megestrol) – Appetite Stimulant for AIDS Patients
`Trilipix® (choline fenofibrate) – Low HDL Cholesterol / High Triglycerides
`(cid:16)
`(cid:16) Yaz® (drospirenone / ethinyl estradiol) – Oral Contraceptive
`(cid:16) Aplenzin® (bupropion HBr) – Depression & Anxiety Disorder (“SSRI”)
`(cid:16) Ritalin LA® (methylphenidate) – Attention Deficit & Hyperactive Disorder (“ADHD”)
`(cid:16) Xyzal® (levocetirizine) – Non-Sedating Antihistamine for Allergic Rhinitis
`(cid:16) Prevacid® (lansoprazole) – Ulcers & Gastroesophageal Reflux Disease (“PPI”)
`
`Analyzed economic issues and survey data to determine whether a generic entrant’s
`non-infringing use would be “insubstantial” in the context of a Hatch-Waxman “Section
`8 Carve-Out”: Actos® (pioglitazone) type II diabetes.
`
`Analyzed possible irreparable harm, balance of hardships, and economic impact on the
`public
`interest of proposed Temporary Restraining Orders and/or Preliminary
`Injunctions on allegedly infringing product sales.
`
`(cid:16) Precedex® (dexmedetomidine) – Sedative for Intubation and Surgery
`(cid:16) Nuvigil® (armodafinil) – Excessive Sleepiness
`(cid:16) Seasonique® (levonorgestrel / ethynil estradiol) – Oral Contraceptive
`
`1200 19th Street NW, Suite 700 (cid:135) W(cid:68)(cid:86)hi(cid:81)(cid:74)t(cid:82)(cid:81), (cid:39)(cid:38) 200(cid:22)(cid:25)
`(cid:82)(cid:73)(cid:73)i(cid:70)e(cid:29) 202(cid:17)(cid:23)(cid:27)1(cid:17)(cid:27)(cid:24)2(cid:23) e(cid:80)(cid:68)i(cid:79)(cid:29) (cid:77)(cid:82)h(cid:81)(cid:17)(cid:86)t(cid:68)i(cid:81)e(cid:86)(cid:35)(cid:81)(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)te(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)(cid:17)(cid:70)(cid:82)(cid:80)
`
`000003
`
`

`

`(cid:45)(cid:82)h(cid:81) (cid:38)(cid:17) St(cid:68)i(cid:81)e(cid:86), (cid:45)r(cid:17)
`(cid:39)ire(cid:70)t(cid:82)r (cid:9) (cid:51)ri(cid:81)(cid:70)i(cid:83)(cid:68)(cid:79), N(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)t (cid:40)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)
`(cid:51)(cid:68)(cid:74)e (cid:23) (cid:82)(cid:73) 9
`
`(cid:16) Ritalin LA® (methylphenidate) – Attention Deficit & Hyperactive Disorder (“ADHD”)
`(cid:16) Glucophage® (metformin) – Type II Diabetes
`Tessalon® (benzonatate) – Cough Suppressant
`(cid:16)
`(cid:16) Various Unapproved (“DESI”) – Topical Pharmaceutical Treatments
`(cid:16) Paxil CR® (paroxetine) – Depression & Anxiety Disorder
`(cid:16) Ethyol® (amifostine) – Ovarian/Neck/Head Cancer Chemo/Radiation side effects
`
`Pharmaceutical Antitrust/Competition
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`Alleged anticompetitive “reverse-payment” patent settlement: Lidoderm® (lidocaine
`patch) pain medication
`
`exclusive
`and
`bundling
`price
`alleging
`counterclaim
`Antitrust
`Epogen®/Aranesp®, Neupogen®/Neulasta® anemia and neutropenia treatments
`
`dealing:
`
`Alleged predation involving brand firm’s launch of an “authorized generic”: Macrobid®
`(nitrofurantoin monohydrate macrocrystals) urinary tract infections
`
`Potential antitrust counterclaims associated with brand firm’s actions to forestall
`generic competition: Paxil CR® (paroxetine) depression & anxiety disorder
`
`(cid:120) Competitive effects and potential antitrust implications of the proposed terms of a bulk
`API supply contract in the market for generic Augmentin® (amoxicillin/clavulanic acid).
`
`(cid:120) Market definition and competitive impacts of a proposed merger under FTC review in
`the relevant pharmaceutical markets for Enbrel® (etanercept) and Kineret® (anakinra),
`biological treatments for rheumatoid arthritis.
`
`(cid:120)
`
`Adequacy of competition and prospective effects of entry in various pharmaceutical
`controlled substance markets as part of five Drug Enforcement Administration hearings
`on the proposed registration of new bulk manufacturers and/or importers of:
`
`opium / concentrate of poppy straw (oxycodone, hydrocodone, morphine, codeine)
`(cid:16)
`cocaine for use as a local anesthetic
`(cid:16)
`(cid:16) methylphenidate for treatment of attention deficit disorder.
`
`Pharmaceutical Commercial Damages
`
`(cid:120) Generic lost profits from delayed FDA approval and generic exclusivity forfeiture due to
`flaws in a contract research organization’s bioequivalence studies: Zoloft® (sertraline)
`depression & anxiety disorder; Zofran ODT® (ondansetron) cancer-related nausea;
`Avelox® (moxifloxicin) antibiotic.
`
`(cid:120)
`
`Financial valuation of a refractory chronic gout drug in relation to a proposed temporary
`restraining order to delay a proposed financial transaction and motion to put owner into
`receivership.
`
`1200 19th Street NW, Suite 700 (cid:135) W(cid:68)(cid:86)hi(cid:81)(cid:74)t(cid:82)(cid:81), (cid:39)(cid:38) 200(cid:22)(cid:25)
`(cid:82)(cid:73)(cid:73)i(cid:70)e(cid:29) 202(cid:17)(cid:23)(cid:27)1(cid:17)(cid:27)(cid:24)2(cid:23) e(cid:80)(cid:68)i(cid:79)(cid:29) (cid:77)(cid:82)h(cid:81)(cid:17)(cid:86)t(cid:68)i(cid:81)e(cid:86)(cid:35)(cid:81)(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)te(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)(cid:17)(cid:70)(cid:82)(cid:80)
`
`000004
`
`

`

`(cid:45)(cid:82)h(cid:81) (cid:38)(cid:17) St(cid:68)i(cid:81)e(cid:86), (cid:45)r(cid:17)
`(cid:39)ire(cid:70)t(cid:82)r (cid:9) (cid:51)ri(cid:81)(cid:70)i(cid:83)(cid:68)(cid:79), N(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)t (cid:40)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)
`(cid:51)(cid:68)(cid:74)e (cid:24) (cid:82)(cid:73) 9
`
`(cid:120) Overcharges to private insurers and State governments associated with alleged over-
`reimbursement of drug costs due to inflated Average Wholesale Prices (“AWPs”):
`Epogen®/Aranesp®, Neupogen®/Neulasta® anemia and neutropenia treatments.
`
`(cid:120)
`
`(cid:120)
`
`Lost profit and shareholder diminution damages due to a U.S. generic firm’s alleged
`failure to purchase various finished dose products from a Jordanian pharmaceutical
`company per terms of the parties’ agreement: Various generic drugs.
`
`Impact of generic entry on an acquired brand company’s financial valuation: Ifex®
`/Mesnex® (ifosfamide/mesna) testicular cancer.
`
`(cid:120) Overcharge damages due to a PBM’s alleged price-fixing of insurance reimbursement
`rates for drug prescriptions applied to a class of independent pharmacies.
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`Stock market event study of the financial impact of an FTC investigation of drug
`products marketed by a pharmaceutical acquisition target. Skelaxin® (metaxalone)
`muscle relaxant.
`
`Shareholder value damages allegedly associated with overpayment for a generic
`biopharmaceutical firm acquisition.
`
`Variety of analyses and research activities associated with a license dispute involving
`U.S. sales of Epogen® and Procrit® (epoetin alfa) anemia.
`
`(cid:16) Methodologies to track licensor/licensee sales by therapeutic indication;
`(cid:16) Methods to reimburse profits on cross-indication sales;
`Lost profits due to allegedly delayed FDA approval;
`(cid:16)
`Financial valuation of market segments.
`(cid:16)
`(cid:16) Detailed analysis of Medicare reimbursement claims data
`(cid:16) Estimation of price erosion due to competition from licensee.
`
`Bankruptcy damages of a large pharmaceutical wholesaler (FoxMeyer Drug) allegedly
`caused by the flawed implementation of a new management information system.
`
`Lost profit/value damages associated with foregone development opportunities for
`drugs to treat obesity, anxiety, depression, insomnia, Alzheimer's, and benign prostate
`hypertrophy, due to massive product liability claims allegedly caused by the Defendant.
`
`Financial analyses to support a fairness opinion for settlement of class action claims
`associated with adverse side effects. Redux® (dexfenfluramine) diet drug.
`
`Valuation analyses to support a fairness opinion for settlement of a shareholder
`treatment for patients undergoing percutaneous
`lawsuit: ReoPro® (abciximab)
`transluminal coronary angioplasty (PCTA) to treat coronary artery disease.
`
`Lost royalty damages for a prospective HIV/AIDS and hepatitis B drug that Defendant
`allegedly failed to develop.
`
`Lost royalty damages for a prospective monoclonal antibody-based drug to treat
`asthma and allergic rhinitis that Defendant allegedly had not timely developed. Xolair®
`(omalizumab).
`
`1200 19th Street NW, Suite 700 (cid:135) W(cid:68)(cid:86)hi(cid:81)(cid:74)t(cid:82)(cid:81), (cid:39)(cid:38) 200(cid:22)(cid:25)
`(cid:82)(cid:73)(cid:73)i(cid:70)e(cid:29) 202(cid:17)(cid:23)(cid:27)1(cid:17)(cid:27)(cid:24)2(cid:23) e(cid:80)(cid:68)i(cid:79)(cid:29) (cid:77)(cid:82)h(cid:81)(cid:17)(cid:86)t(cid:68)i(cid:81)e(cid:86)(cid:35)(cid:81)(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)te(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)(cid:17)(cid:70)(cid:82)(cid:80)
`
`000005
`
`

`

`(cid:45)(cid:82)h(cid:81) (cid:38)(cid:17) St(cid:68)i(cid:81)e(cid:86), (cid:45)r(cid:17)
`(cid:39)ire(cid:70)t(cid:82)r (cid:9) (cid:51)ri(cid:81)(cid:70)i(cid:83)(cid:68)(cid:79), N(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)t (cid:40)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)
`(cid:51)(cid:68)(cid:74)e (cid:25) (cid:82)(cid:73) 9
`
`(cid:120)
`
`(cid:120)
`
`Lost royalty damages in the U.S., Europe, and East Asia due to the alleged failure of
`the licensee to obtain regulatory approval for a Hepatitis B vaccine and a cancer drug.
`
`Lost profit and royalty damages due to the licensee’s alleged failed to supply bulk
`product and maintain patents for a synthetic hepatitis B and C drug in East Asia.
`
`Pharmaceutical Consulting
`
`(cid:120)
`
`Assisted in a pharmacoeconomic analysis used to formulate a client’s future marketing
`strategy for promoting new uses of current and prospective pacemaker technologies.
`
`(cid:120) Developed mathematical programming model to generate profit-maximizing production
`strategies for a pharmaceutical company's jointly-produced plasma fractions products.
`
`Economic/Competition Analysis – Other Industries
`
`Developed economic and supporting quantitative analyses of the level, nature, and conditions of
`industry competition in a variety of markets in antitrust and other legal/regulatory contexts. Evaluated
`the likely economic impact of proposed government regulation of industry in terms of prices, demand,
`investment, entry and exit, industry structure, employment, etc. Specific projects include the
`following:
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`Analyzed competition issues raised in an antitrust counterclaim involving Standardbred
`Harness Horseracing.
`
`Performed various analyses of company financial data, operations data, and survey
`results to analyze pyramid scheme allegations regarding the U.S. Operations of a
`Multi-Level Marking firm manufacturing and selling health foods.
`
`Analyzed ARCO franchisee claims of unfair competition associated with British
`Petroleum’s pricing of wholesale gasoline supply.
`
`(cid:120) Conducted economic analyses related to proposed class certifications in litigations
`involving price-fixing and monopolization allegations associated with the sale of:
`
`(cid:16)
`
`(cid:16)
`
`(cid:16)
`
`plastics additives used in the manufacture of products incorporating poly-vinyl
`chloride (“PVC”) and certain engineering resins
`organic peroxides used in the manufacture of various types of plastic products
`
`computer operating and applications software
`
`(cid:120)
`
`(cid:120)
`
`Assessed the validity of potential antitrust claims against the dominant supplier of
`personal computer operating systems, internet browser software, and applications
`software arising from the company’s alleged attempts to impede the adoption of a
`competitor’s internet-based “middleware” platform software that threatened the
`incumbent’s monopoly power.
`
`Analyzed price pass-through of alleged monopoly surcharges associated with
`certification of a class of indirect purchasers claiming damages from the purchase of
`
`1200 19th Street NW, Suite 700 (cid:135) W(cid:68)(cid:86)hi(cid:81)(cid:74)t(cid:82)(cid:81), (cid:39)(cid:38) 200(cid:22)(cid:25)
`(cid:82)(cid:73)(cid:73)i(cid:70)e(cid:29) 202(cid:17)(cid:23)(cid:27)1(cid:17)(cid:27)(cid:24)2(cid:23) e(cid:80)(cid:68)i(cid:79)(cid:29) (cid:77)(cid:82)h(cid:81)(cid:17)(cid:86)t(cid:68)i(cid:81)e(cid:86)(cid:35)(cid:81)(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)te(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)(cid:17)(cid:70)(cid:82)(cid:80)
`
`000006
`
`

`

`(cid:45)(cid:82)h(cid:81) (cid:38)(cid:17) St(cid:68)i(cid:81)e(cid:86), (cid:45)r(cid:17)
`(cid:39)ire(cid:70)t(cid:82)r (cid:9) (cid:51)ri(cid:81)(cid:70)i(cid:83)(cid:68)(cid:79), N(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)t (cid:40)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)
`(cid:51)(cid:68)(cid:74)e 7 (cid:82)(cid:73) 9
`
`the defendant’s computer operating system, word processing and spreadsheet
`software.
`
`As part of a price discrimination case, analyzed the economics of manufacturer-retail
`agency relationships in the cellular telephone industry, including determination of the
`attributes of effective retail agents and the impact of product life-cycles on the optimal
`retail channel.
`
`Performed statistical analyses of product differentiation and market delineation in the
`luxury automobile market in support of a price discrimination case involving the "gray
`market" for Mercedez Benz automobile parts.
`
`Performed economic analyses of the competitive, price, and financial impacts of
`proposed environmental and health regulations affecting manufacturers and customers
`various products.
`
`Formaldehyde
`(cid:16)
`(cid:16) Methylenedianiline
`(cid:16) Audio/video/computer Magnetic Tapes & Disks
`(cid:16) Crushed Stone Aggregate
`
`Performed analyses in support of a theoretical and empirical study of the natural
`monopoly rational for prohibiting the private delivery of third-class addressed mail.
`
`Performed industry analyses of the economic incentive effects in the Paint Industry of
`imposing a waste-end tax on the land disposal of hazardous wastes as a supplemental
`source of financing for the U.S. EPA’s “Superfund” program.
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`Damages Analysis – Other Industries
`
`Supervised calculation of damages based on analysis of product supply and demand, product life-
`cycles, prices, market share, entry and exit, first-mover effects, costs of capital, internal rates of
`return, opportunities for mitigation, stock price changes, and other economic factors. Specific work
`experience includes the following:
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`(cid:120)
`
`Analyzed lost profit and direct cost damages sustained due to installation of allegedly
`defective refractory lining material in regenerator and third stage separator equipment
`at the FCC units of various oil refineries.
`
`Estimated lost repair profit damages associated with alleged infringement of design
`and utility patents for portable data terminals used by delivery firms and the US Postal
`Service to scan and store package delivery information.
`
`Estimated damages incurred by the owner of certain FCC wireless licenses in
`California that resulted from an accounting firm’s alleged misrepresentation of a
`licensee’s financial condition.
`
`Performed valuation of a wireless telecommunications company in Venezuela to
`estimate damages associated with the alleged failure of a U.S. telecommunications
`company to purchase shares in compliance with a put option agreement.
`
`1200 19th Street NW, Suite 700 (cid:135) W(cid:68)(cid:86)hi(cid:81)(cid:74)t(cid:82)(cid:81), (cid:39)(cid:38) 200(cid:22)(cid:25)
`(cid:82)(cid:73)(cid:73)i(cid:70)e(cid:29) 202(cid:17)(cid:23)(cid:27)1(cid:17)(cid:27)(cid:24)2(cid:23) e(cid:80)(cid:68)i(cid:79)(cid:29) (cid:77)(cid:82)h(cid:81)(cid:17)(cid:86)t(cid:68)i(cid:81)e(cid:86)(cid:35)(cid:81)(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)te(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)(cid:17)(cid:70)(cid:82)(cid:80)
`
`000007
`
`

`

`(cid:45)(cid:82)h(cid:81) (cid:38)(cid:17) St(cid:68)i(cid:81)e(cid:86), (cid:45)r(cid:17)
`(cid:39)ire(cid:70)t(cid:82)r (cid:9) (cid:51)ri(cid:81)(cid:70)i(cid:83)(cid:68)(cid:79), N(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)t (cid:40)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)
`(cid:51)(cid:68)(cid:74)e (cid:27) (cid:82)(cid:73) 9
`
`(cid:120)
`
`Estimated the appropriate compensation due to a U.S. coastal shipping company
`associated with the alleged U.S. Government “taking” of the company’s oil tank barges
`and other capital assets that resulted from the double-hull provisions of the 1990 Oil
`Pollution Act.
`
`(cid:120) Calculated damages generated by alleged breaches associated with the provision of
`consulting services to upgrade a management information system in the computer
`distribution industry.
`
`(cid:120) Calculated lost profit damages associated with a telecommunications company’s
`alleged breach of a marketing contract with a wireless telecommunications company.
`
`(cid:120) Calculated damages to royalty owners of a CO2 gas field resulting from alleged under-
`pricing of well-head CO2 and alleged tariff overcharges for pipeline transportation to
`enhanced oil recovery fields.
`
`(cid:120) Calculated lost profit and lost investment damages in a European breach-of-contract
`case associated with a patent for a new running shoe technology.
`
`(cid:120)
`
`Evaluated the theoretical framework for estimating damages in multiple breach-of-
`contract cases in the electric utility industry.
`
`(cid:120) Drafted report on a theoretical framework appropriate for estimating damages as part
`of defendant's submission to a European Tribunal, and evaluated plaintiff's damages
`estimates in a breach-of-contract case involving wood panel presses.
`
`(cid:120)
`
`Analyzed costs and estimated lost profit margins in support of expert testimony
`involving alleged infringement of patents related to X-Y pen plotters.
`
`International Trade
`
`Estimated the magnitude of import dumping margins and the resulting injury of dumped and
`subsidized imports to the domestic industry. Met with Department of Commerce staff to argue for
`modifications in margin estimates. Analyzed International Trade Commission questionnaire
`responses. Prepared exhibits for hearings. Evaluated and developed economic models of domestic
`industry impacts of unfairly traded imports.
`
`(cid:120) Developed economic arguments to support briefs and expert economic testimony in a
`dumping and subsidy case involving U.S. imports of seamless steel pipe from
`Argentina, Brazil, Germany, and Italy. Evaluated the applicability of ITC's computer
`model measuring injury to the domestic industry. Identified conceptual flaws in
`opposing experts' use of an oligopoly model to estimate price effects of imports.
`
`(cid:120)
`
`(cid:120)
`
`Performed a variety of economic, financial, and statistical analyses in a dumping
`investigation of U.S. imports of natural and enriched uranium from the former Soviet
`Union. Estimated less-than-fair-value margins based on construction of average costs.
`Developed market model of world uranium trade to estimate injury to the domestic
`industry and to simulate price impacts of alternative import restriction mechanisms
`proposed in Suspension Agreement negotiations.
`
`Analyzed and identified statistical flaws in ITC's econometric model of the domestic
`price and quantity impact of unfairly traded potato imports from Canada.
`
`1200 19th Street NW, Suite 700 (cid:135) W(cid:68)(cid:86)hi(cid:81)(cid:74)t(cid:82)(cid:81), (cid:39)(cid:38) 200(cid:22)(cid:25)
`(cid:82)(cid:73)(cid:73)i(cid:70)e(cid:29) 202(cid:17)(cid:23)(cid:27)1(cid:17)(cid:27)(cid:24)2(cid:23) e(cid:80)(cid:68)i(cid:79)(cid:29) (cid:77)(cid:82)h(cid:81)(cid:17)(cid:86)t(cid:68)i(cid:81)e(cid:86)(cid:35)(cid:81)(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)te(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)(cid:17)(cid:70)(cid:82)(cid:80)
`
`000008
`
`

`

`(cid:45)(cid:82)h(cid:81) (cid:38)(cid:17) St(cid:68)i(cid:81)e(cid:86), (cid:45)r(cid:17)
`(cid:39)ire(cid:70)t(cid:82)r (cid:9) (cid:51)ri(cid:81)(cid:70)i(cid:83)(cid:68)(cid:79), N(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)t (cid:40)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)
`(cid:51)(cid:68)(cid:74)e 9 (cid:82)(cid:73) 9
`
`Product Liability/Risk Assessment
`
`(cid:120) Developed a statistical model used by industry to assess the risk of injury and death
`associated with All Terrain Vehicles (ATVs). Performed risk and cost-benefit analyses
`of various regulatory proposals considered by the U.S. Consumer Product Safety
`Commission. Evaluated risk of injury and death to specific plaintiffs in support of expert
`testimony in ATV product liability litigation.
`
`(cid:120)
`
`(cid:120)
`
`Performed statistical analyses of the risk of injury and death associated with chain
`saws and radial arm saws in support of expert testimony in regulatory hearings and
`product liability litigation.
`
`Assisted in estimating reduction in health risks associated with proposed regulations
`limiting airborne emissions from industrial boilers.
`
`December 2017
`
`1200 19th Street NW, Suite 700 (cid:135) W(cid:68)(cid:86)hi(cid:81)(cid:74)t(cid:82)(cid:81), (cid:39)(cid:38) 200(cid:22)(cid:25)
`(cid:82)(cid:73)(cid:73)i(cid:70)e(cid:29) 202(cid:17)(cid:23)(cid:27)1(cid:17)(cid:27)(cid:24)2(cid:23) e(cid:80)(cid:68)i(cid:79)(cid:29) (cid:77)(cid:82)h(cid:81)(cid:17)(cid:86)t(cid:68)i(cid:81)e(cid:86)(cid:35)(cid:81)(cid:68)(cid:89)i(cid:74)(cid:68)(cid:81)te(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)i(cid:70)(cid:86)(cid:17)(cid:70)(cid:82)(cid:80)
`
`000009
`
`